Background and Importance. Unruptured supraclinoid aneurysms can be treated by surgery or endovascular therapy, but, when individualizing each patient, the associated comorbidities must be considered to select the best approach, follow-up control studies and treatment.Clinical Presentation: Sudden oppressive headache in the frontal-orbital and right retroocular region.
Conclusion:Given the demonstration of an aneurysmal volumetric growth of 25% in 10 months, we consider that the risk of rupture of an unruptured aneurysms in patients with inflammatory and autoimmune comorbidities is higher than in patients outside of this context. We suggest carrying out a control study at least every 6 months to assess the evolution of the aneurysm and reconsider the possibility of endovascular treatment, with the placement of a flow diverter being an appropriate therapeutic option for its management.